The University of Chicago Header Logo

Mark J. Ratain

Concepts (1155)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Antineoplastic Agents
167
2024
2347
14.940
Why?
Neoplasms
191
2024
2868
14.710
Why?
Pharmacogenetics
75
2022
429
10.230
Why?
Glucuronosyltransferase
50
2015
184
6.820
Why?
Camptothecin
53
2020
189
6.540
Why?
Antineoplastic Combined Chemotherapy Protocols
69
2021
2424
4.850
Why?
Clinical Trials, Phase II as Topic
24
2022
173
4.820
Why?
Antineoplastic Agents, Phytogenic
45
2014
276
4.810
Why?
Clinical Trials, Phase I as Topic
32
2022
149
4.390
Why?
Humans
540
2024
85610
4.070
Why?
Clinical Trials as Topic
42
2020
1166
3.740
Why?
Medical Oncology
17
2022
356
3.510
Why?
Pyridines
19
2022
309
3.360
Why?
Research Design
30
2022
589
3.250
Why?
Antibodies, Monoclonal, Humanized
18
2023
925
3.130
Why?
Drug-Related Side Effects and Adverse Reactions
13
2022
197
2.820
Why?
Food-Drug Interactions
8
2017
18
2.810
Why?
Lung Neoplasms
25
2023
2248
2.790
Why?
Dose-Response Relationship, Drug
65
2022
1959
2.770
Why?
Carcinoma, Non-Small-Cell Lung
18
2023
1071
2.770
Why?
Protein Kinase Inhibitors
16
2022
588
2.680
Why?
Polymorphism, Genetic
31
2021
819
2.530
Why?
Benzenesulfonates
12
2012
64
2.510
Why?
Drug Approval
6
2023
62
2.480
Why?
Maximum Tolerated Dose
26
2022
270
2.460
Why?
Randomized Controlled Trials as Topic
17
2022
843
2.440
Why?
Piperidines
7
2022
181
2.350
Why?
Aged
206
2021
18254
2.350
Why?
Drug Labeling
9
2017
41
2.170
Why?
Drug Administration Schedule
58
2020
917
2.140
Why?
Adenine
12
2022
85
2.130
Why?
Middle Aged
219
2021
24842
2.130
Why?
Genotype
53
2022
1845
2.040
Why?
Prostatic Neoplasms, Castration-Resistant
5
2018
104
2.010
Why?
Male
240
2022
40659
1.980
Why?
Antimetabolites, Antineoplastic
14
2020
236
1.960
Why?
United States Food and Drug Administration
13
2024
126
1.950
Why?
Drugs, Investigational
11
2018
37
1.900
Why?
Economics, Pharmaceutical
3
2023
9
1.900
Why?
Enzyme Inhibitors
13
2017
631
1.890
Why?
Androstenes
5
2021
42
1.870
Why?
Polymorphism, Single Nucleotide
35
2021
2345
1.870
Why?
Drug Interactions
24
2022
248
1.870
Why?
Sirolimus
7
2018
168
1.870
Why?
Female
246
2023
44181
1.850
Why?
Precision Medicine
19
2022
390
1.840
Why?
Biopsy
11
2022
1159
1.840
Why?
Biomarkers, Tumor
20
2021
1458
1.840
Why?
Pharmacogenomic Testing
16
2022
96
1.840
Why?
Adult
190
2022
25442
1.820
Why?
Aged, 80 and over
87
2021
6464
1.800
Why?
Fluorouracil
29
2021
556
1.790
Why?
Neutropenia
28
2019
214
1.720
Why?
Deoxycytidine
11
2019
237
1.670
Why?
Antineoplastic Agents, Immunological
5
2022
185
1.640
Why?
Paclitaxel
22
2021
458
1.540
Why?
Antibodies, Monoclonal
11
2021
1373
1.530
Why?
Biomedical Research
5
2023
373
1.530
Why?
United States
37
2024
6585
1.470
Why?
Etoposide
17
2009
195
1.460
Why?
Drug Industry
6
2021
53
1.460
Why?
Genome, Human
10
2019
754
1.430
Why?
Pharmacology, Clinical
4
2020
9
1.420
Why?
ErbB Receptors
8
2021
485
1.400
Why?
Treatment Outcome
59
2023
7908
1.400
Why?
Breast Neoplasms
25
2023
2855
1.370
Why?
Administration, Oral
31
2021
684
1.350
Why?
Cytochrome P-450 CYP2D6
9
2022
52
1.340
Why?
Patient Selection
11
2018
683
1.330
Why?
Microsomes, Liver
17
2017
49
1.310
Why?
Thrombocytopenia
18
2022
181
1.300
Why?
Endpoint Determination
10
2016
60
1.300
Why?
Suramin
11
2004
27
1.280
Why?
Sulfonamides
9
2017
296
1.280
Why?
Quinazolines
10
2010
218
1.280
Why?
Pyrimidines
6
2021
370
1.240
Why?
Infusions, Intravenous
38
2017
430
1.240
Why?
Melanoma
6
2020
451
1.240
Why?
Protein-Tyrosine Kinases
7
2012
302
1.220
Why?
Cisplatin
20
2021
604
1.190
Why?
Colorectal Neoplasms
16
2020
919
1.180
Why?
Phenylurea Compounds
16
2018
113
1.160
Why?
Drug Dosage Calculations
5
2020
16
1.150
Why?
Angiogenesis Inhibitors
10
2021
309
1.140
Why?
Food
4
2018
85
1.130
Why?
Ketoconazole
6
2017
25
1.120
Why?
Genome-Wide Association Study
24
2022
1601
1.120
Why?
Molecular Targeted Therapy
5
2018
266
1.110
Why?
Drug Prescriptions
8
2022
140
1.080
Why?
Kidney Neoplasms
13
2014
614
1.060
Why?
Pharmaceutical Preparations
5
2024
92
1.050
Why?
Genetic Therapy
2
2023
342
1.040
Why?
Glucuronides
14
2017
34
1.040
Why?
Genetic Variation
17
2020
1346
1.030
Why?
Tamoxifen
6
2018
167
1.020
Why?
Niacinamide
15
2014
116
1.020
Why?
Area Under Curve
28
2019
333
1.010
Why?
Models, Biological
26
2019
1740
1.010
Why?
HIV Protease Inhibitors
2
2022
21
1.000
Why?
Anemia
6
2022
128
1.000
Why?
Isoenzymes
9
2015
271
1.000
Why?
Imides
9
2001
26
0.990
Why?
Phosphotransferases
2
2017
65
0.990
Why?
Prospective Studies
27
2022
4156
0.990
Why?
Orphan Drug Production
1
2023
3
0.970
Why?
Carcinoma, Renal Cell
11
2014
420
0.970
Why?
Isoquinolines
9
2001
72
0.960
Why?
Drug Monitoring
8
2021
118
0.950
Why?
Carbolines
3
2022
8
0.950
Why?
Decision Support Systems, Clinical
5
2019
103
0.940
Why?
Heterocyclic Compounds, 4 or More Rings
3
2022
16
0.940
Why?
Leukemia, Hairy Cell
26
1994
186
0.940
Why?
Conflict of Interest
5
2015
67
0.940
Why?
Indoles
6
2017
317
0.930
Why?
Clinical Trials, Phase III as Topic
8
2015
168
0.930
Why?
Body Surface Area
6
2022
36
0.930
Why?
Liver
18
2020
1223
0.930
Why?
Ethics Committees, Research
2
2022
33
0.910
Why?
Prodrugs
5
2008
46
0.900
Why?
Leukemia
9
2021
317
0.890
Why?
Piperazines
3
2022
271
0.880
Why?
Quinoxalines
4
2014
50
0.870
Why?
Ritonavir
1
2022
12
0.870
Why?
Drug Costs
2
2020
62
0.860
Why?
Arylamine N-Acetyltransferase
2
2021
11
0.850
Why?
Fear
1
2022
71
0.850
Why?
Liver Diseases
4
2007
236
0.850
Why?
Leucovorin
18
2021
218
0.840
Why?
Physicians
3
2021
668
0.840
Why?
Antibiotics, Antineoplastic
5
2012
110
0.840
Why?
Anemia, Sickle Cell
1
2023
131
0.840
Why?
Diarrhea
10
2009
180
0.830
Why?
Computer Simulation
6
2023
1073
0.830
Why?
Patents as Topic
1
2021
12
0.830
Why?
Janus Kinase 2
1
2021
57
0.830
Why?
Patient Harm
1
2021
7
0.820
Why?
Peripheral Nervous System Diseases
6
2020
85
0.820
Why?
Industry
3
2023
16
0.810
Why?
Antifungal Agents
3
2007
117
0.810
Why?
Health Care Costs
3
2021
237
0.810
Why?
Biological Products
2
2020
142
0.800
Why?
Bevacizumab
12
2023
279
0.800
Why?
Cardiotoxicity
1
2021
9
0.790
Why?
Topotecan
9
2005
45
0.790
Why?
Methyltransferases
5
2013
181
0.790
Why?
Metabolic Clearance Rate
17
2017
121
0.790
Why?
Informed Consent
11
2022
265
0.780
Why?
Taxoids
6
2016
129
0.760
Why?
Multidrug Resistance-Associated Proteins
5
2013
27
0.750
Why?
Pharmacogenomic Variants
4
2021
41
0.740
Why?
Prostatic Neoplasms
12
2018
1696
0.730
Why?
Creatinine
6
2015
335
0.720
Why?
Cytochrome P-450 CYP3A
10
2017
43
0.720
Why?
Adenosine A2 Receptor Antagonists
1
2019
13
0.700
Why?
Cost-Benefit Analysis
6
2023
448
0.700
Why?
Research
4
2019
251
0.700
Why?
Triazoles
4
2012
96
0.690
Why?
Topoisomerase II Inhibitors
4
2009
26
0.690
Why?
Interleukin-6
1
2020
254
0.690
Why?
Doxorubicin
9
2007
288
0.690
Why?
Programmed Cell Death 1 Receptor
1
2020
158
0.680
Why?
TOR Serine-Threonine Kinases
5
2018
181
0.670
Why?
Interferon-alpha
16
2004
232
0.660
Why?
Caffeine
1
2019
81
0.650
Why?
Point-of-Care Systems
3
2019
140
0.650
Why?
National Cancer Institute (U.S.)
7
2023
70
0.650
Why?
Physician's Role
2
2017
179
0.640
Why?
Metabolome
2
2017
46
0.640
Why?
Megestrol Acetate
1
2017
10
0.640
Why?
Kidney Diseases
4
2007
417
0.630
Why?
Patient Education as Topic
2
2019
348
0.630
Why?
Parkinson Disease
1
2019
132
0.630
Why?
Protein Kinases
3
2009
207
0.630
Why?
Hydroxamic Acids
3
2014
49
0.620
Why?
Pyrazoles
5
2022
153
0.620
Why?
Practice Patterns, Physicians'
7
2021
575
0.610
Why?
Medical Order Entry Systems
1
2017
25
0.610
Why?
Dihydrouracil Dehydrogenase (NADP)
10
2006
29
0.600
Why?
Immunotherapy
2
2020
620
0.600
Why?
Nontherapeutic Human Experimentation
7
2017
20
0.600
Why?
Carboplatin
5
2021
286
0.600
Why?
Neovascularization, Pathologic
5
2018
352
0.590
Why?
Perioperative Care
5
2022
159
0.580
Why?
Guanine
4
2002
208
0.570
Why?
Recombinant Proteins
30
2017
1012
0.570
Why?
Germ-Line Mutation
7
2020
323
0.560
Why?
Leukopenia
12
2002
65
0.560
Why?
Capecitabine
6
2020
87
0.550
Why?
Pancreatic Neoplasms
4
2019
640
0.550
Why?
Drug Resistance, Neoplasm
9
2020
589
0.540
Why?
Topoisomerase I Inhibitors
7
2020
33
0.540
Why?
Guidelines as Topic
2
2019
162
0.540
Why?
Kidney
6
2015
1226
0.540
Why?
RNA, Messenger
14
2018
1974
0.540
Why?
Attitude of Health Personnel
4
2019
635
0.540
Why?
Oxidoreductases
10
2002
111
0.530
Why?
Introns
4
2013
288
0.530
Why?
Genetic Predisposition to Disease
15
2019
2254
0.530
Why?
Depsipeptides
1
2015
29
0.530
Why?
Aryl Hydrocarbon Hydroxylases
3
2013
44
0.530
Why?
Uracil
7
2002
70
0.530
Why?
Prostate-Specific Antigen
5
2018
345
0.530
Why?
Meaningful Use
1
2014
2
0.530
Why?
Morpholines
1
2015
65
0.530
Why?
Oligonucleotides, Antisense
2
2005
69
0.520
Why?
Professional Practice
1
2015
45
0.510
Why?
Carbazoles
2
2005
51
0.510
Why?
Head and Neck Neoplasms
10
2008
1047
0.510
Why?
Renal Insufficiency
2
2009
113
0.500
Why?
Time Factors
22
2020
5186
0.500
Why?
Lymphoma
7
2021
262
0.500
Why?
Cohort Studies
18
2019
2738
0.500
Why?
Hypertension, Pulmonary
3
2022
344
0.500
Why?
Bilirubin
13
2010
124
0.490
Why?
Reproducibility of Results
11
2021
2680
0.490
Why?
Adenocarcinoma
5
2018
1159
0.490
Why?
Regression Analysis
14
2010
593
0.490
Why?
Sample Size
3
2011
129
0.480
Why?
Interferon Type I
17
1990
175
0.480
Why?
Young Adult
22
2020
5918
0.480
Why?
Patient Protection and Affordable Care Act
1
2014
65
0.470
Why?
Biological Availability
7
2017
91
0.470
Why?
Linkage Disequilibrium
7
2013
473
0.470
Why?
Estrogen Antagonists
1
2013
47
0.470
Why?
Risk Assessment
19
2021
2243
0.470
Why?
Program Development
1
2014
124
0.470
Why?
Dietary Fats
1
2014
133
0.470
Why?
Ambulatory Care
2
2014
174
0.460
Why?
Drug Delivery Systems
2
2012
177
0.460
Why?
Hearing Loss
1
2013
51
0.460
Why?
Catechol O-Methyltransferase
1
2013
65
0.460
Why?
Proto-Oncogene Proteins c-raf
2
2004
47
0.460
Why?
Food Labeling
1
2012
8
0.460
Why?
Models, Statistical
8
2020
573
0.450
Why?
Drug Therapy
5
2016
70
0.450
Why?
Indazoles
5
2017
68
0.450
Why?
Phenotype
19
2020
2362
0.450
Why?
Cladribine
5
2004
35
0.450
Why?
Enzymes
2
2006
47
0.440
Why?
Vascular Endothelial Growth Factor A
5
2018
407
0.440
Why?
Universities
1
2013
135
0.440
Why?
Private Sector
2
2011
19
0.440
Why?
Practice Guidelines as Topic
7
2019
1024
0.440
Why?
Glucuronates
8
2007
22
0.430
Why?
Medicine
3
2007
88
0.430
Why?
Snake Venoms
2
2015
10
0.430
Why?
Clinical Protocols
2
2014
154
0.420
Why?
Investments
1
2011
6
0.420
Why?
Pyrazolones
2
2002
3
0.420
Why?
Patient Safety
2
2020
209
0.420
Why?
Warfarin
3
2019
103
0.420
Why?
Antineoplastic Agents, Hormonal
7
2018
150
0.410
Why?
Commerce
1
2011
28
0.410
Why?
Mass Media
1
2011
26
0.410
Why?
Vinblastine
7
1998
108
0.410
Why?
Technology, Pharmaceutical
2
2009
30
0.410
Why?
Neoplasm Staging
14
2021
1929
0.410
Why?
Haplotypes
7
2012
642
0.410
Why?
Cost Sharing
1
2011
13
0.400
Why?
Academic Medical Centers
1
2014
375
0.400
Why?
Germ Cells
1
2012
120
0.400
Why?
Interleukin-17
1
2011
98
0.400
Why?
Hypertension
3
2021
1134
0.400
Why?
Mutation
8
2021
3946
0.390
Why?
Kinetics
10
2017
1512
0.390
Why?
Gene Expression Regulation
5
2020
1903
0.390
Why?
Clinical Decision-Making
5
2021
254
0.390
Why?
Body Weight
4
2020
458
0.390
Why?
Insurance, Health, Reimbursement
1
2011
59
0.390
Why?
Renal Insufficiency, Chronic
1
2015
349
0.390
Why?
Eating
2
2012
166
0.390
Why?
Health Resources
1
2011
76
0.390
Why?
Cyclosporine
5
2007
234
0.380
Why?
Research Subjects
9
2007
73
0.380
Why?
Alleles
6
2017
1124
0.380
Why?
Aminopyridines
2
2022
32
0.370
Why?
Patient Portals
2
2020
14
0.370
Why?
Follow-Up Studies
15
2021
3608
0.370
Why?
Ovarian Neoplasms
3
2008
737
0.360
Why?
Cost Savings
2
2020
66
0.360
Why?
Drug Evaluation
17
2002
141
0.360
Why?
Population Groups
1
2009
41
0.360
Why?
Dinucleotide Repeats
1
2009
13
0.350
Why?
Hepatic Insufficiency
1
2009
1
0.350
Why?
Drug Design
8
2011
124
0.350
Why?
Acetylation
6
2021
121
0.350
Why?
Promoter Regions, Genetic
7
2012
932
0.350
Why?
Decision Support Techniques
2
2021
160
0.350
Why?
Fatigue
8
2022
173
0.350
Why?
Substrate Specificity
5
2017
347
0.350
Why?
Blood Pressure Monitoring, Ambulatory
1
2009
83
0.350
Why?
Cell Line, Tumor
9
2018
2416
0.340
Why?
Genetics, Population
2
2009
394
0.340
Why?
Drug Discovery
1
2009
103
0.340
Why?
Prescription Drugs
2
2019
35
0.340
Why?
Phosphorylcholine
1
2008
28
0.340
Why?
Organizations, Nonprofit
1
2008
8
0.340
Why?
Anesthesiology
2
2022
154
0.330
Why?
Biomarkers
2
2014
1701
0.330
Why?
Double-Blind Method
9
2019
1812
0.330
Why?
Biomedical Technology
1
2008
20
0.330
Why?
Immunosuppressive Agents
4
2007
973
0.330
Why?
Organoplatinum Compounds
4
2020
94
0.330
Why?
Cytochrome P-450 Enzyme System
7
2008
79
0.320
Why?
Data Interpretation, Statistical
5
2016
296
0.320
Why?
Disease Progression
6
2012
1519
0.320
Why?
Myelodysplastic Syndromes
3
2014
343
0.320
Why?
Drug Packaging
3
2020
7
0.310
Why?
Evidence-Based Medicine
5
2021
426
0.310
Why?
Government Regulation
2
2007
48
0.310
Why?
Salvage Therapy
4
2008
232
0.310
Why?
Genetic Privacy
1
2007
12
0.310
Why?
Tubulin Modulators
2
2020
24
0.310
Why?
Liposomes
2
2004
92
0.310
Why?
Decision Making
5
2018
640
0.300
Why?
Health Knowledge, Attitudes, Practice
3
2020
505
0.300
Why?
DNA-Binding Proteins
4
2012
1204
0.300
Why?
Phenobarbital
4
2006
33
0.300
Why?
Models, Genetic
1
2012
926
0.300
Why?
Prejudice
1
2007
49
0.300
Why?
Histone Deacetylase Inhibitors
3
2014
85
0.300
Why?
Medical Records
2
2007
120
0.300
Why?
Glomerular Filtration Rate
2
2011
384
0.290
Why?
Intestinal Absorption
3
2017
123
0.290
Why?
Delivery of Health Care
3
2023
418
0.290
Why?
Patient Acceptance of Health Care
2
2020
234
0.290
Why?
Naphthalimides
9
2001
17
0.290
Why?
Technology Transfer
1
2006
3
0.290
Why?
Radiosurgery
2
2021
265
0.290
Why?
Disease-Free Survival
8
2016
1203
0.280
Why?
Cytochrome P-450 CYP3A Inhibitors
2
2017
5
0.280
Why?
Erlotinib Hydrochloride
5
2010
90
0.280
Why?
Quantitative Trait Loci
5
2020
568
0.280
Why?
Organophosphonates
9
2001
50
0.280
Why?
Vascular Endothelial Growth Factor Receptor-2
3
2015
81
0.280
Why?
Carcinoma, Hepatocellular
2
2013
376
0.280
Why?
Drug Therapy, Combination
6
2019
894
0.280
Why?
Abiraterone Acetate
2
2018
8
0.280
Why?
Neoplasms, Hormone-Dependent
1
2005
40
0.270
Why?
Prognosis
14
2021
3653
0.270
Why?
O(6)-Methylguanine-DNA Methyltransferase
3
2002
118
0.270
Why?
Pharmacy and Therapeutics Committee
3
2010
5
0.270
Why?
Cytochrome P-450 CYP2C9
2
2019
21
0.270
Why?
Liver Neoplasms
3
2013
712
0.270
Why?
Receptor, trkA
1
2005
14
0.260
Why?
Neuroendocrine Tumors
1
2006
100
0.260
Why?
Survival Analysis
12
2018
1535
0.260
Why?
Receptor Protein-Tyrosine Kinases
2
2010
153
0.260
Why?
Anthraquinones
2
2002
8
0.260
Why?
Chicago
4
2014
1366
0.260
Why?
Dipeptides
1
2004
46
0.250
Why?
Maytansine
1
2004
9
0.250
Why?
Genomics
3
2019
702
0.250
Why?
Thionucleotides
2
2002
56
0.250
Why?
Granulocyte-Macrophage Colony-Stimulating Factor
5
2004
111
0.250
Why?
Information Dissemination
3
2019
103
0.250
Why?
Clinical Medicine
3
2015
34
0.250
Why?
Fasting
2
2018
161
0.250
Why?
Patient Compliance
2
2005
224
0.250
Why?
Gene Expression Regulation, Enzymologic
4
2010
211
0.250
Why?
Neoplasm Recurrence, Local
7
2018
1289
0.240
Why?
Acetyltransferases
2
2021
29
0.240
Why?
Granulocyte Colony-Stimulating Factor
7
2003
164
0.240
Why?
Glutathione Transferase
6
2005
111
0.240
Why?
Animals
25
2016
26414
0.240
Why?
Product Surveillance, Postmarketing
1
2023
37
0.240
Why?
Greenhouse Gases
1
2023
1
0.240
Why?
Interleukin-2
7
2004
245
0.240
Why?
Genetic Markers
3
2018
476
0.240
Why?
Pyrazines
4
2000
84
0.240
Why?
Government
1
2023
9
0.230
Why?
Physician-Patient Relations
4
2019
608
0.230
Why?
Sensory Receptor Cells
2
2014
35
0.230
Why?
Fever
3
2020
123
0.230
Why?
Neoplasms, Squamous Cell
2
2008
19
0.230
Why?
Prednisone
4
2018
255
0.220
Why?
Dioxolanes
1
2002
8
0.220
Why?
Survival Rate
10
2021
1855
0.220
Why?
Lymphoma, Non-Hodgkin
3
2010
261
0.220
Why?
DNA Damage
2
2017
362
0.220
Why?
Apoptosis
2
2008
1676
0.220
Why?
Chemistry, Pharmaceutical
2
2004
59
0.220
Why?
Metabolic Networks and Pathways
3
2013
77
0.220
Why?
Lactams
1
2022
10
0.220
Why?
DNA, Antisense
1
2002
15
0.220
Why?
Lactams, Macrocyclic
1
2022
14
0.220
Why?
Alanine
2
2019
85
0.220
Why?
ATP-Binding Cassette Transporters
2
2016
141
0.220
Why?
Risk Factors
11
2021
5366
0.220
Why?
Triazines
2
2019
47
0.220
Why?
Transcription, Genetic
3
2017
1127
0.220
Why?
Tramadol
1
2022
14
0.210
Why?
Anilides
2
2013
46
0.210
Why?
Reimbursement, Incentive
1
2022
37
0.210
Why?
Leukemia, Myeloid
2
2014
249
0.210
Why?
Kv1.3 Potassium Channel
1
2021
14
0.210
Why?
Pain Management
2
2021
127
0.210
Why?
Celecoxib
2
2019
31
0.210
Why?
Uridine Diphosphate
2
1998
5
0.210
Why?
Oxidation-Reduction
3
2017
372
0.210
Why?
Genetic Testing
4
2019
530
0.210
Why?
Stomatitis
5
2004
30
0.210
Why?
Biotransformation
6
2009
50
0.210
Why?
Cytosine
1
2002
127
0.200
Why?
Mercaptopurine
3
2009
53
0.200
Why?
Oligodeoxyribonucleotides, Antisense
1
2001
16
0.200
Why?
Aminoquinolines
1
2001
17
0.200
Why?
Indenes
1
2001
9
0.200
Why?
Acrylamides
1
2021
30
0.200
Why?
Intercalating Agents
2
1993
12
0.200
Why?
Epothilones
2
2019
13
0.200
Why?
Human Genome Project
1
2001
19
0.200
Why?
Nitriles
2
2012
143
0.200
Why?
Proteinuria
1
2021
106
0.200
Why?
Patient Participation
4
2015
212
0.200
Why?
Hockey
1
2021
9
0.200
Why?
Research Personnel
2
2001
66
0.200
Why?
Hematologic Neoplasms
3
2014
327
0.200
Why?
Anesthetics
1
2021
48
0.200
Why?
Government Agencies
1
2020
10
0.200
Why?
Protein Kinase C
1
2002
270
0.200
Why?
Collagen
1
2002
267
0.200
Why?
Patient-Centered Care
1
2023
201
0.200
Why?
Anticarcinogenic Agents
3
2013
70
0.190
Why?
Rheumatology
1
2021
27
0.190
Why?
Antidotes
2
1997
23
0.190
Why?
Sarcoma
4
2009
210
0.190
Why?
Bile
2
2002
57
0.190
Why?
Organizational Policy
1
2001
55
0.190
Why?
Signal Transduction
6
2013
3222
0.190
Why?
Analgesics, Opioid
2
2021
402
0.190
Why?
Genotyping Techniques
3
2018
68
0.190
Why?
Albumins
2
2019
133
0.190
Why?
Safety
4
2010
152
0.190
Why?
Thymidylate Synthase
4
2003
13
0.190
Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
2008
171
0.190
Why?
Testicular Neoplasms
2
2019
104
0.190
Why?
Peptide Fragments
1
2002
459
0.190
Why?
Remission Induction
17
2008
721
0.190
Why?
Nausea
5
2022
175
0.190
Why?
Analgesics
1
2021
115
0.190
Why?
Splenectomy
9
1992
82
0.190
Why?
Societies, Medical
2
2019
570
0.190
Why?
Models, Theoretical
6
2014
476
0.190
Why?
Anesthesia
1
2022
163
0.190
Why?
Equivalence Trials as Topic
1
2019
5
0.190
Why?
Algorithms
3
2019
1823
0.190
Why?
Neoplasm Metastasis
10
2018
1053
0.190
Why?
Schools, Medical
1
2001
123
0.180
Why?
Europe
1
2020
308
0.180
Why?
DNA, Neoplasm
3
2018
265
0.180
Why?
C-Reactive Protein
1
2020
189
0.180
Why?
Bone Marrow
12
2001
431
0.180
Why?
Drug Utilization
1
2020
65
0.180
Why?
Leukocytes, Mononuclear
4
2018
196
0.180
Why?
Circadian Rhythm
2
2015
300
0.180
Why?
Receptors, Cytoplasmic and Nuclear
2
2017
122
0.180
Why?
Neoplasms, Second Primary
2
1992
252
0.180
Why?
Inpatients
1
2022
292
0.180
Why?
Response Evaluation Criteria in Solid Tumors
2
2018
56
0.180
Why?
Chemotherapy, Adjuvant
5
2011
458
0.180
Why?
Leukocyte Count
10
1996
219
0.180
Why?
Cytidine Deaminase
1
2019
43
0.180
Why?
Hepatocytes
4
2013
125
0.170
Why?
Ethics, Medical
4
2008
306
0.170
Why?
Leukemia, Myeloid, Acute
4
2008
751
0.170
Why?
Benzamides
2
2013
225
0.170
Why?
Tegafur
2
1999
17
0.170
Why?
Stomach Neoplasms
1
2021
264
0.170
Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
2005
366
0.170
Why?
Quality Indicators, Health Care
1
2020
143
0.170
Why?
Lymphoproliferative Disorders
3
1996
106
0.170
Why?
Exanthema
2
2009
35
0.170
Why?
Withholding Treatment
1
2019
111
0.170
Why?
Equilibrative Nucleoside Transporter 1
1
2018
2
0.170
Why?
Medication Adherence
1
2020
129
0.170
Why?
Bayes Theorem
1
2020
357
0.170
Why?
Receptors, IgG
1
2018
52
0.170
Why?
Singapore
1
2018
16
0.170
Why?
Cetuximab
4
2021
113
0.160
Why?
Receptors, Estrogen
3
2016
380
0.160
Why?
Phosphatidylinositol 3-Kinases
2
2016
261
0.160
Why?
Dehydroepiandrosterone
1
2018
51
0.160
Why?
Blood Pressure
3
2014
1136
0.160
Why?
Troleandomycin
1
2017
3
0.160
Why?
HSP90 Heat-Shock Proteins
1
2018
46
0.160
Why?
Bone Marrow Diseases
3
1993
40
0.160
Why?
Proton Magnetic Resonance Spectroscopy
1
2017
12
0.160
Why?
Lymphocytes, Tumor-Infiltrating
1
2019
123
0.160
Why?
Career Choice
1
2019
139
0.160
Why?
Liver Function Tests
4
2007
94
0.160
Why?
Erythropoietin
3
2013
91
0.160
Why?
Statistics as Topic
3
1993
237
0.150
Why?
Surveys and Questionnaires
9
2020
2452
0.150
Why?
History, 20th Century
2
2011
312
0.150
Why?
Receptors, Calcitriol
1
2018
129
0.150
Why?
Receptors, Vascular Endothelial Growth Factor
2
2014
68
0.150
Why?
Combined Modality Therapy
11
2021
1657
0.150
Why?
Diphtheria Toxin
4
1998
20
0.150
Why?
Terminology as Topic
1
2019
216
0.150
Why?
Adrenal Cortex Diseases
1
1996
6
0.150
Why?
Addison Disease
1
1996
4
0.150
Why?
Ribosomal Protein S6 Kinases, 70-kDa
2
2018
44
0.150
Why?
Specialization
2
2007
65
0.150
Why?
Motor Neuron Disease
1
1997
21
0.150
Why?
Valproic Acid
1
1997
24
0.150
Why?
Therapeutic Human Experimentation
2
1993
20
0.150
Why?
Neural Conduction
1
1997
69
0.150
Why?
Cardiovascular Agents
2
2015
56
0.150
Why?
Cytochrome P-450 CYP2C19
2
2014
7
0.150
Why?
Glioma
1
1999
285
0.150
Why?
Demyelinating Diseases
1
1997
68
0.150
Why?
Intersectoral Collaboration
1
2016
10
0.150
Why?
Metformin
1
2018
126
0.140
Why?
Biliary Tract
1
1996
13
0.140
Why?
Periodicals as Topic
1
2019
167
0.140
Why?
Healthy Volunteers
1
2017
140
0.140
Why?
Testosterone
1
2018
268
0.140
Why?
Gene Expression Regulation, Neoplastic
4
2010
1196
0.140
Why?
Critical Care
1
2019
365
0.140
Why?
Neoplasm Proteins
5
2016
532
0.140
Why?
Atazanavir Sulfate
1
2015
1
0.140
Why?
Cyclophosphamide
7
2002
299
0.140
Why?
Floxuridine
2
1993
11
0.140
Why?
Hyperbilirubinemia
1
2015
20
0.140
Why?
Jaundice
1
2015
13
0.140
Why?
Polyneuropathies
1
2016
27
0.140
Why?
Hydroxyurea
6
1998
239
0.140
Why?
Chromatography, High Pressure Liquid
5
2004
313
0.140
Why?
Drug Eruptions
2
2006
35
0.140
Why?
Glucocorticoids
1
2018
345
0.140
Why?
Flavonoids
4
2007
85
0.140
Why?
Tumor Microenvironment
1
2019
410
0.140
Why?
Random Allocation
6
2008
332
0.140
Why?
Attitude to Health
4
2017
219
0.140
Why?
Placebos
3
2017
217
0.140
Why?
Pneumonia, Viral
1
2020
311
0.140
Why?
Selection Bias
2
2011
37
0.130
Why?
Advisory Committees
1
2015
90
0.130
Why?
Collagen Type I
1
2015
62
0.130
Why?
Sulfonic Acids
1
1995
9
0.130
Why?
Treatment Failure
2
2011
284
0.130
Why?
Hydrocortisone
1
1996
295
0.130
Why?
Nitrosamines
1
2014
8
0.130
Why?
Gene Expression Profiling
6
2013
1378
0.130
Why?
Nedocromil
1
2014
6
0.130
Why?
Inactivation, Metabolic
2
2006
8
0.130
Why?
Loss of Heterozygosity
1
2014
85
0.130
Why?
Sex Characteristics
1
1997
312
0.130
Why?
Naphthyridines
1
2015
51
0.130
Why?
DNA Primers
2
2006
541
0.130
Why?
Comprehension
5
2000
79
0.130
Why?
Adolescent
11
2020
8905
0.130
Why?
Lymphopenia
2
2012
28
0.130
Why?
Busulfan
1
2014
39
0.130
Why?
Fees and Charges
1
2014
14
0.130
Why?
Phthalazines
1
2014
38
0.130
Why?
Drug Synergism
5
2018
303
0.130
Why?
Epirubicin
3
2021
14
0.130
Why?
Drug Resistance
3
1993
256
0.130
Why?
Aldehyde Oxidase
1
2014
3
0.120
Why?
Forced Expiratory Volume
1
2014
119
0.120
Why?
Neoplasms, Glandular and Epithelial
1
2015
74
0.120
Why?
Azacitidine
1
2014
136
0.120
Why?
Pyrroles
2
2015
184
0.120
Why?
Thromboembolism
1
2014
117
0.120
Why?
Child
9
2020
6866
0.120
Why?
Cytochrome P-450 CYP2C8
1
2013
3
0.120
Why?
Receptors, Interleukin-2
5
1998
66
0.120
Why?
Sex Factors
5
2020
1043
0.120
Why?
Disclosure
5
2000
108
0.120
Why?
Organic Cation Transporter 1
1
2013
1
0.120
Why?
Hepatocyte Nuclear Factor 1
1
2013
30
0.120
Why?
Portraits as Topic
1
2013
6
0.120
Why?
Medicare
1
2017
397
0.120
Why?
Anti-Asthmatic Agents
1
2014
76
0.120
Why?
Patient Outcome Assessment
1
2014
83
0.120
Why?
Arteries
1
2014
173
0.120
Why?
Carcinoma, Small Cell
3
1997
134
0.120
Why?
Carcinoma, Squamous Cell
2
1999
1075
0.120
Why?
Brain Diseases
1
1995
179
0.120
Why?
Erythropoiesis
1
2013
52
0.120
Why?
Comorbidity
1
2017
936
0.120
Why?
Brain Neoplasms
1
1999
762
0.120
Why?
Imatinib Mesylate
1
2013
126
0.120
Why?
Organic Anion Transporters, Sodium-Independent
1
2013
5
0.120
Why?
Axons
1
2014
173
0.110
Why?
Prevalence
1
2017
1230
0.110
Why?
Pathology, Molecular
1
2013
34
0.110
Why?
Leukemia, Prolymphocytic
1
1992
3
0.110
Why?
Transfection
4
2011
894
0.110
Why?
Health Policy
1
2015
179
0.110
Why?
Adaptation, Physiological
1
1995
306
0.110
Why?
Trastuzumab
2
2023
65
0.110
Why?
Off-Label Use
1
2012
16
0.110
Why?
Skin Neoplasms
5
2020
541
0.110
Why?
Leukemia, B-Cell
1
1992
23
0.110
Why?
Citrus paradisi
1
2012
5
0.110
Why?
Quality of Life
5
2020
1551
0.110
Why?
Conserved Sequence
1
2013
209
0.110
Why?
Nicotine
1
2014
193
0.110
Why?
DNA Topoisomerases, Type II
2
2009
19
0.110
Why?
Androstenols
1
2012
3
0.110
Why?
Binding, Competitive
2
2010
145
0.110
Why?
Multifactorial Inheritance
1
2014
153
0.110
Why?
Leukemia, Monocytic, Acute
1
1992
14
0.110
Why?
Kaplan-Meier Estimate
2
2011
857
0.110
Why?
Orchiectomy
1
2012
67
0.110
Why?
National Institutes of Health (U.S.)
2
2017
115
0.110
Why?
Venous Thromboembolism
1
2014
148
0.110
Why?
Cells, Cultured
3
2020
2798
0.110
Why?
Gene Dosage
2
2013
207
0.110
Why?
Hyperlipidemias
1
2012
95
0.110
Why?
Hydroxylation
2
2009
16
0.110
Why?
Logistic Models
4
1999
1176
0.110
Why?
Postmenopause
1
2012
96
0.110
Why?
Students
1
2013
146
0.110
Why?
Soft Tissue Neoplasms
2
2009
126
0.110
Why?
Hemoglobins
2
1991
178
0.110
Why?
Therapeutic Equivalency
2
2021
12
0.100
Why?
Anticoagulants
2
2019
402
0.100
Why?
Phosphorylation
2
2018
1099
0.100
Why?
Peptides
1
2015
639
0.100
Why?
Pentostatin
7
2002
30
0.100
Why?
Rats
5
2013
3966
0.100
Why?
Adenoma
1
2013
231
0.100
Why?
Fibroblasts
1
2014
728
0.100
Why?
Proto-Oncogene Proteins c-ret
1
2011
21
0.100
Why?
Patient Care
1
2012
99
0.100
Why?
Thalidomide
1
2011
53
0.100
Why?
Oligonucleotide Array Sequence Analysis
3
2008
684
0.100
Why?
Androstadienes
1
2011
72
0.100
Why?
Cyclosporins
1
1991
59
0.100
Why?
Reverse Transcriptase Polymerase Chain Reaction
3
2008
874
0.100
Why?
Maryland
1
2011
35
0.100
Why?
Verapamil
1
1991
48
0.100
Why?
Tumor Cells, Cultured
4
2002
1039
0.100
Why?
Hyperglycemia
1
2012
176
0.100
Why?
Multivariate Analysis
5
2009
995
0.100
Why?
Life Expectancy
1
2011
84
0.100
Why?
Analgesics, Non-Narcotic
1
2011
46
0.100
Why?
Acetaminophen
1
2011
54
0.100
Why?
Pharmacoepidemiology
1
2010
6
0.100
Why?
Predictive Value of Tests
5
2021
1664
0.100
Why?
Feasibility Studies
5
2004
750
0.100
Why?
Gene Frequency
4
2008
675
0.100
Why?
Thyroxine
2
2015
344
0.100
Why?
Healthcare Disparities
1
2015
361
0.100
Why?
Insurance, Health
1
2012
153
0.100
Why?
DNA Repair
2
2003
356
0.100
Why?
Hepatocyte Nuclear Factor 1-alpha
2
2009
79
0.100
Why?
Cholestasis
1
1990
46
0.100
Why?
Electroencephalography
1
1995
702
0.100
Why?
Amino Acid Substitution
1
2011
339
0.100
Why?
Microtubules
2
2004
117
0.100
Why?
Efficiency
1
2010
40
0.090
Why?
Smoking
1
2014
604
0.090
Why?
Burkitt Lymphoma
1
2010
31
0.090
Why?
Glycosylation
1
2010
129
0.090
Why?
Severity of Illness Index
3
2020
1773
0.090
Why?
Antibodies, Monoclonal, Murine-Derived
1
2010
78
0.090
Why?
Proto-Oncogene Proteins B-raf
2
2013
137
0.090
Why?
Indinavir
2
2010
3
0.090
Why?
Half-Life
5
2008
96
0.090
Why?
Daunorubicin
2
2008
78
0.090
Why?
History, 21st Century
1
2011
175
0.090
Why?
Vomiting
4
2014
191
0.090
Why?
Rituximab
1
2010
116
0.090
Why?
Cell Cycle Proteins
2
2010
386
0.090
Why?
Cardiovascular Diseases
2
2015
823
0.090
Why?
Cell Proliferation
3
2016
1568
0.090
Why?
Software
2
2017
651
0.090
Why?
Motivation
4
2012
285
0.090
Why?
Kidney Function Tests
2
2007
124
0.090
Why?
Publishing
1
2010
89
0.090
Why?
Membrane Proteins
1
2016
1192
0.090
Why?
Lymphoma, B-Cell
1
2010
104
0.090
Why?
International Normalized Ratio
1
2009
38
0.090
Why?
Mucositis
1
2009
17
0.090
Why?
Podophyllotoxin
3
1994
10
0.090
Why?
Pain
2
2022
387
0.090
Why?
Blood Cell Count
6
1999
79
0.090
Why?
Polymerase Chain Reaction
2
2013
926
0.090
Why?
Werner Syndrome
1
2008
1
0.080
Why?
Topoisomerase Inhibitors
1
2008
2
0.080
Why?
Acute Disease
4
2014
819
0.080
Why?
RecQ Helicases
1
2008
6
0.080
Why?
Pilot Projects
4
2019
834
0.080
Why?
Forecasting
2
2008
303
0.080
Why?
Exodeoxyribonucleases
1
2008
14
0.080
Why?
Genes, Neoplasm
1
2008
37
0.080
Why?
Platinum Compounds
1
2008
30
0.080
Why?
Recombinant Fusion Proteins
4
1998
553
0.080
Why?
Developed Countries
1
2008
24
0.080
Why?
Health Care Sector
1
2008
13
0.080
Why?
Enterohepatic Circulation
1
2008
3
0.080
Why?
Personal Autonomy
4
1998
111
0.080
Why?
Hep G2 Cells
3
2013
48
0.080
Why?
Colonic Neoplasms
1
2012
550
0.080
Why?
MicroRNAs
1
2013
534
0.080
Why?
Protease Inhibitors
1
2008
72
0.080
Why?
Injections, Subcutaneous
3
2004
117
0.080
Why?
Stereoisomerism
3
2008
102
0.080
Why?
Immunotoxins
2
1998
14
0.080
Why?
Tomography, X-Ray Computed
2
2016
2557
0.080
Why?
Receptor, ErbB-2
2
2014
210
0.080
Why?
Lymphoma, Follicular
1
2008
70
0.080
Why?
Economics, Medical
1
2007
6
0.080
Why?
MAP Kinase Signaling System
1
2008
192
0.080
Why?
Phosphoproteins
1
2009
253
0.080
Why?
Carmustine
2
2000
70
0.080
Why?
Everolimus
1
2007
40
0.080
Why?
Leukemia, Lymphocytic, Chronic, B-Cell
1
2008
136
0.080
Why?
Gene Amplification
1
2007
131
0.080
Why?
Hematopoietic Stem Cell Transplantation
1
2014
877
0.080
Why?
Insurance
1
2007
10
0.080
Why?
Evolution, Molecular
1
2013
811
0.080
Why?
Hypotension
3
2004
68
0.080
Why?
Age Factors
4
2014
1831
0.080
Why?
Hodgkin Disease
1
2008
176
0.080
Why?
Tissue Distribution
2
2021
290
0.080
Why?
Patient Reported Outcome Measures
2
2019
156
0.080
Why?
Employment
1
2007
52
0.080
Why?
In Situ Hybridization, Fluorescence
2
2010
348
0.080
Why?
Immunoenzyme Techniques
2
2002
303
0.070
Why?
Adaptor Proteins, Signal Transducing
1
2009
302
0.070
Why?
Observer Variation
1
2008
601
0.070
Why?
Medication Errors
1
2007
36
0.070
Why?
Radiotherapy
2
2003
326
0.070
Why?
Base Sequence
3
2008
2326
0.070
Why?
Nogalamycin
1
1986
2
0.070
Why?
Tea
1
2006
18
0.070
Why?
Serum Albumin
3
1995
129
0.070
Why?
Catechin
1
2006
18
0.070
Why?
Molecular Structure
1
2007
287
0.070
Why?
Thymidine
1
1986
58
0.070
Why?
Lymphoma, Large B-Cell, Diffuse
1
2008
151
0.070
Why?
Photosensitivity Disorders
1
2006
15
0.070
Why?
Case-Control Studies
3
2020
1796
0.070
Why?
Cross-Over Studies
2
2011
397
0.070
Why?
Structure-Activity Relationship
1
2007
407
0.070
Why?
Keratosis
1
2006
21
0.070
Why?
Complementary Therapies
1
2007
53
0.070
Why?
Asthma
1
2014
942
0.070
Why?
Retrospective Studies
8
2013
8342
0.070
Why?
Probability
1
2007
356
0.070
Why?
Infusion Pumps
5
1989
25
0.070
Why?
DNA Topoisomerases, Type I
1
2006
23
0.070
Why?
Genes, ras
1
2006
96
0.070
Why?
Drug Combinations
3
2010
221
0.070
Why?
Mice
6
2016
11193
0.070
Why?
Molecular Sequence Data
3
2008
3027
0.070
Why?
Patients
1
2007
102
0.070
Why?
Foot Dermatoses
1
1985
3
0.070
Why?
Rats, Wistar
2
1997
295
0.070
Why?
Hand Dermatoses
1
1985
9
0.070
Why?
Neutrophils
3
2002
303
0.070
Why?
Protein Structure, Tertiary
1
2007
734
0.070
Why?
Adsorption
1
2005
53
0.070
Why?
Alternative Splicing
2
2008
201
0.070
Why?
Furans
1
2005
16
0.070
Why?
Filgrastim
2
2003
56
0.070
Why?
Oligodeoxyribonucleotides
1
2005
126
0.070
Why?
Consensus Sequence
1
2005
64
0.070
Why?
Phenylenediamines
1
2004
5
0.070
Why?
Meperidine
1
2004
13
0.060
Why?
Thiophenes
3
2000
48
0.060
Why?
Oxidoreductases, N-Demethylating
1
2004
12
0.060
Why?
Injections, Intravenous
3
2004
243
0.060
Why?
Cytochrome P-450 Enzyme Inhibitors
1
2004
10
0.060
Why?
Drug Hypersensitivity
1
2004
38
0.060
Why?
Capsules
1
2004
38
0.060
Why?
Transaminases
1
2004
34
0.060
Why?
Quinolones
1
2004
60
0.060
Why?
In Vitro Techniques
3
2015
986
0.060
Why?
B-Lymphocytes
2
2008
722
0.060
Why?
Mixed Function Oxygenases
1
2004
68
0.060
Why?
Coformycin
3
1989
9
0.060
Why?
Tissue Fixation
2
2014
40
0.060
Why?
Gene Transfer Techniques
1
2004
152
0.060
Why?
Paraffin Embedding
2
2014
78
0.060
Why?
Formaldehyde
2
2014
52
0.060
Why?
Pyrrolidines
1
2004
58
0.060
Why?
Neoplasm Transplantation
1
2004
388
0.060
Why?
Drug Screening Assays, Antitumor
2
2010
78
0.060
Why?
Research Support as Topic
1
2004
79
0.060
Why?
Greenhouse Effect
1
2023
1
0.060
Why?
Ethics, Research
1
2004
52
0.060
Why?
Mouth Mucosa
2
2014
66
0.060
Why?
Idoxuridine
2
1993
16
0.060
Why?
Hypnotics and Sedatives
1
2004
124
0.060
Why?
Pelvis
1
2003
92
0.060
Why?
Alkaline Phosphatase
4
2002
131
0.060
Why?
CD56 Antigen
1
2002
18
0.060
Why?
Chromium
1
2002
17
0.060
Why?
Child, Preschool
3
2020
3598
0.060
Why?
Endostatins
1
2002
6
0.060
Why?
Therapies, Investigational
1
2022
17
0.060
Why?
Pharmacists
1
2022
30
0.060
Why?
Hepatitis C
1
2005
208
0.050
Why?
CHO Cells
1
2002
187
0.050
Why?
Omeprazole
1
2022
11
0.050
Why?
Succinylcholine
1
2022
14
0.050
Why?
Syndrome
1
2003
439
0.050
Why?
Hydralazine
1
2022
20
0.050
Why?
Protein Kinase C-alpha
1
2002
27
0.050
Why?
Morphine
1
2003
131
0.050
Why?
Killer Cells, Natural
2
2002
265
0.050
Why?
X-ray Repair Cross Complementing Protein 1
1
2021
2
0.050
Why?
Epoprostenol
1
2022
46
0.050
Why?
Population
1
2002
35
0.050
Why?
Familial Primary Pulmonary Hypertension
1
2022
58
0.050
Why?
Flow Cytometry
2
2002
674
0.050
Why?
Immunohistochemistry
2
2004
1751
0.050
Why?
Oxycodone
1
2022
35
0.050
Why?
Anorexia
1
2001
30
0.050
Why?
Oligonucleotides
1
2002
92
0.050
Why?
Cricetinae
1
2002
560
0.050
Why?
Point Mutation
1
2002
246
0.050
Why?
Carbon Radioisotopes
1
2001
35
0.050
Why?
Interinstitutional Relations
1
2001
28
0.050
Why?
Receptors, Interleukin-6
1
2020
17
0.050
Why?
Disease Models, Animal
1
2008
2218
0.050
Why?
Anthropometry
1
2001
74
0.050
Why?
Complement System Proteins
1
2001
81
0.050
Why?
Data Collection
2
2000
371
0.050
Why?
Cardiac Output
1
2001
156
0.050
Why?
Blood Coagulation
1
2001
91
0.050
Why?
Neurites
1
2020
35
0.050
Why?
Longitudinal Studies
2
2014
998
0.050
Why?
Ferredoxin-NADP Reductase
1
2020
15
0.050
Why?
Sequence Analysis, DNA
2
2018
852
0.050
Why?
Aspartate Aminotransferases
1
2000
73
0.050
Why?
Methylenetetrahydrofolate Reductase (NADPH2)
1
2020
26
0.050
Why?
Carcinoma
1
2004
432
0.050
Why?
Proprotein Convertase 9
1
2020
20
0.050
Why?
Macrolides
1
2000
30
0.050
Why?
Lactones
1
2000
28
0.050
Why?
Evaluation Studies as Topic
1
2000
270
0.050
Why?
Interferons
4
1990
131
0.050
Why?
Glutathione
2
2000
103
0.050
Why?
Administration, Intravenous
1
2019
49
0.040
Why?
Colonic Polyps
1
2000
126
0.040
Why?
Gene Expression
2
2014
1279
0.040
Why?
Polyethylene Glycols
1
2001
361
0.040
Why?
Drug Recalls
1
2019
12
0.040
Why?
Hypoxia
1
2004
635
0.040
Why?
Codeine
1
2019
12
0.040
Why?
Health Plan Implementation
1
2019
56
0.040
Why?
Analysis of Variance
2
2004
912
0.040
Why?
Myosin Heavy Chains
1
2019
88
0.040
Why?
Feces
1
2001
310
0.040
Why?
Myosin Type II
1
2019
48
0.040
Why?
Hypolipidemic Agents
1
2020
102
0.040
Why?
Receptors, G-Protein-Coupled
1
2020
112
0.040
Why?
Hospitalization
2
2019
836
0.040
Why?
NFATC Transcription Factors
1
2018
28
0.040
Why?
Aldehyde Dehydrogenase
1
1998
14
0.040
Why?
Hematologic Diseases
2
1996
79
0.040
Why?
Mycosis Fungoides
1
1998
23
0.040
Why?
Alkyl and Aryl Transferases
1
1998
15
0.040
Why?
Ribonucleosides
2
1989
25
0.040
Why?
Crigler-Najjar Syndrome
1
1998
3
0.040
Why?
Organic Anion Transporters
2
2009
27
0.040
Why?
Zidovudine
1
1998
16
0.040
Why?
Cytochrome P-450 CYP2D6 Inhibitors
1
2018
5
0.040
Why?
Nitrophenols
1
1998
11
0.040
Why?
Human Umbilical Vein Endothelial Cells
1
2018
63
0.040
Why?
Anticonvulsants
1
1999
126
0.040
Why?
High-Throughput Nucleotide Sequencing
1
2021
450
0.040
Why?
Treatment Refusal
1
1998
60
0.040
Why?
Program Evaluation
1
2019
295
0.040
Why?
Anti-Inflammatory Agents
1
2020
336
0.040
Why?
Infant
2
2020
3029
0.040
Why?
Exons
2
2011
450
0.040
Why?
Dose-Response Relationship, Radiation
1
2018
188
0.040
Why?
Causality
1
1998
81
0.040
Why?
DNA Methylation
1
2002
619
0.040
Why?
Cancer Survivors
1
2019
84
0.040
Why?
Alcohol Dehydrogenase
1
1997
42
0.040
Why?
Consent Forms
2
1995
11
0.040
Why?
Antihypertensive Agents
1
2022
516
0.040
Why?
Vinca Alkaloids
1
1997
3
0.040
Why?
Multicenter Studies as Topic
2
2015
148
0.040
Why?
Cosyntropin
1
1996
5
0.040
Why?
Pain, Postoperative
1
2019
237
0.040
Why?
Isotretinoin
1
1997
23
0.040
Why?
Thiotepa
2
2004
32
0.040
Why?
Radiotherapy Dosage
1
2018
467
0.040
Why?
Health Personnel
1
2019
197
0.040
Why?
Patient Satisfaction
1
2000
449
0.040
Why?
Adrenocorticotropic Hormone
1
1996
131
0.040
Why?
Tetrahydrofolates
1
1996
13
0.040
Why?
Aldosterone
1
1996
65
0.040
Why?
Hospital Mortality
1
2019
346
0.040
Why?
Disease Management
1
2019
326
0.040
Why?
Neoplasm Grading
1
2018
352
0.040
Why?
Morphine Derivatives
2
2008
8
0.040
Why?
Magnetic Resonance Imaging
1
2008
3316
0.040
Why?
User-Computer Interface
1
2017
184
0.040
Why?
Social Perception
1
2017
95
0.040
Why?
Neuropsychological Tests
1
2018
497
0.040
Why?
Antigens, Neoplasm
2
2009
324
0.040
Why?
Keratoacanthoma
1
1996
4
0.040
Why?
Mitoxantrone
1
1996
68
0.040
Why?
Biological Transport
2
2002
395
0.040
Why?
Vitamin D
1
2018
260
0.030
Why?
Lymphatic Metastasis
1
2018
480
0.030
Why?
Tertiary Care Centers
1
2016
94
0.030
Why?
Digestive System Diseases
1
1996
18
0.030
Why?
Life Tables
1
1995
48
0.030
Why?
Transcription Factors
2
2014
1534
0.030
Why?
Quality Control
1
2016
117
0.030
Why?
Transcriptional Activation
1
2016
279
0.030
Why?
Bleomycin
2
1993
98
0.030
Why?
Microsomes
1
2015
35
0.030
Why?
Membrane Transport Proteins
1
2016
166
0.030
Why?
Lung
2
2014
1149
0.030
Why?
Communication
1
2019
436
0.030
Why?
Interferon-gamma
2
1988
436
0.030
Why?
Cyclin-Dependent Kinase Inhibitor p15
1
2014
24
0.030
Why?
Blast Crisis
1
1995
32
0.030
Why?
Chi-Square Distribution
1
1996
362
0.030
Why?
Immunocompromised Host
1
1996
137
0.030
Why?
Bias
2
1995
127
0.030
Why?
Rats, Sprague-Dawley
1
1998
1209
0.030
Why?
Chromatography, Liquid
2
2010
104
0.030
Why?
Chromosome Mapping
2
2011
1070
0.030
Why?
Coma
1
1995
44
0.030
Why?
Linear Models
1
1996
416
0.030
Why?
Blotting, Western
2
2008
779
0.030
Why?
Body Mass Index
1
1998
765
0.030
Why?
Cyclin-Dependent Kinase Inhibitor p21
1
2014
74
0.030
Why?
Peroxisome-Targeting Signal 1 Receptor
1
2014
3
0.030
Why?
Myeloablative Agonists
1
2014
34
0.030
Why?
Tumor Burden
1
2016
288
0.030
Why?
Prostate
1
2018
367
0.030
Why?
Prostatectomy
1
2018
452
0.030
Why?
Nervous System Diseases
1
1995
150
0.030
Why?
Budesonide
1
2014
44
0.030
Why?
Antineoplastic Protocols
1
2014
9
0.030
Why?
Lymphocytes
3
2004
459
0.030
Why?
Cyclohexanecarboxylic Acids
1
1994
17
0.030
Why?
Blindness
1
1994
41
0.030
Why?
Electronic Health Records
1
2017
317
0.030
Why?
DNA, Complementary
2
2007
392
0.030
Why?
Cell Line
2
2010
2462
0.030
Why?
Intracellular Signaling Peptides and Proteins
1
2016
377
0.030
Why?
Erythrocyte Count
1
2013
23
0.030
Why?
Arylsulfotransferase
1
2013
4
0.030
Why?
Body Height
1
2014
99
0.030
Why?
Clonal Evolution
1
2013
15
0.030
Why?
Sulfotransferases
1
2013
19
0.030
Why?
Reference Standards
1
2014
158
0.030
Why?
Blood Platelets
1
1994
149
0.030
Why?
Proportional Hazards Models
2
2008
855
0.030
Why?
Dacarbazine
1
1994
102
0.030
Why?
Odds Ratio
1
2015
675
0.030
Why?
Solute Carrier Organic Anion Transporter Family Member 1B3
1
2013
4
0.030
Why?
Drug Stability
1
2013
48
0.030
Why?
Anthracenes
1
1993
15
0.030
Why?
Class I Phosphatidylinositol 3-Kinases
1
2013
53
0.030
Why?
Regulatory Factor X Transcription Factors
1
2012
11
0.030
Why?
Astrocytoma
1
1993
82
0.030
Why?
DNA Copy Number Variations
1
2014
171
0.030
Why?
Frozen Sections
1
2013
48
0.030
Why?
Ethical Review
1
1992
8
0.030
Why?
Cattle
1
2013
372
0.030
Why?
Insurance Claim Review
1
2012
41
0.030
Why?
Blood
1
1993
69
0.030
Why?
Receptor, EphA5
1
2012
2
0.030
Why?
Blood Transfusion
2
1991
158
0.030
Why?
Databases, Factual
1
2016
799
0.030
Why?
Gene-Environment Interaction
1
2013
100
0.030
Why?
Sepsis
1
1996
299
0.030
Why?
Dogs
1
2013
682
0.030
Why?
Imidazoles
1
2013
162
0.030
Why?
Chromosomes, Human, Pair 21
1
1992
54
0.030
Why?
ras Proteins
1
2013
128
0.030
Why?
Insurance Benefits
1
2012
8
0.030
Why?
Chromosomes, Human, Pair 11
1
1992
105
0.030
Why?
Up-Regulation
1
2014
710
0.030
Why?
Least-Squares Analysis
1
1991
48
0.030
Why?
Intellectual Property
1
2011
3
0.030
Why?
Hydrogen-Ion Concentration
1
2013
492
0.030
Why?
Monocytes
3
1994
214
0.030
Why?
Evidence-Based Practice
1
2012
45
0.030
Why?
Species Specificity
1
2013
678
0.030
Why?
DNA Mutational Analysis
1
2013
526
0.030
Why?
Carcinoma, Merkel Cell
1
1991
15
0.030
Why?
Pan troglodytes
1
2013
196
0.030
Why?
Comparative Effectiveness Research
1
2012
53
0.030
Why?
Mice, Knockout
1
2016
1908
0.030
Why?
Luminescent Measurements
1
2011
57
0.030
Why?
Carcinoma, Neuroendocrine
1
2011
28
0.030
Why?
Taiwan
1
2011
23
0.030
Why?
3' Untranslated Regions
1
2011
92
0.020
Why?
Allelic Imbalance
1
2011
20
0.020
Why?
Glioblastoma
1
1993
253
0.020
Why?
Translocation, Genetic
1
1992
265
0.020
Why?
Genetic Loci
1
2012
249
0.020
Why?
Macaca mulatta
1
2013
458
0.020
Why?
Public Sector
1
2010
12
0.020
Why?
Microfilament Proteins
1
2012
206
0.020
Why?
Toxicity Tests
1
2010
13
0.020
Why?
Principal Component Analysis
1
2011
155
0.020
Why?
Receptors, Growth Factor
1
2010
52
0.020
Why?
Epigenesis, Genetic
1
2014
466
0.020
Why?
Gas Chromatography-Mass Spectrometry
2
2002
40
0.020
Why?
Antibody Formation
1
1991
171
0.020
Why?
Tandem Mass Spectrometry
1
2010
102
0.020
Why?
Hymecromone
1
2010
4
0.020
Why?
Glucuronic Acid
1
2010
11
0.020
Why?
Imipramine
1
2010
16
0.020
Why?
Cloning, Molecular
1
2011
646
0.020
Why?
Serine Endopeptidases
1
2010
145
0.020
Why?
Oncogene Proteins, Fusion
1
2010
128
0.020
Why?
Intestinal Mucosa
1
2015
787
0.020
Why?
Biocatalysis
1
2010
51
0.020
Why?
Gene Deletion
1
2011
328
0.020
Why?
Genetic Vectors
1
2011
438
0.020
Why?
Aging
1
1994
688
0.020
Why?
Microtubule-Associated Proteins
1
2010
176
0.020
Why?
Protein Binding
1
2013
1450
0.020
Why?
Mice, Inbred C57BL
1
2016
3070
0.020
Why?
Cooperative Behavior
1
2010
173
0.020
Why?
Demography
1
2009
177
0.020
Why?
Leukemia L1210
1
1988
12
0.020
Why?
DNA Breaks, Double-Stranded
1
2009
63
0.020
Why?
Proto-Oncogene Proteins c-met
1
2010
199
0.020
Why?
Melphalan
1
1989
97
0.020
Why?
Werner Syndrome Helicase
1
2008
1
0.020
Why?
Survivors
1
2010
225
0.020
Why?
Osteolysis
1
1988
14
0.020
Why?
Midazolam
1
2008
48
0.020
Why?
Thiones
2
2000
10
0.020
Why?
Antigens, Differentiation, T-Lymphocyte
1
1988
95
0.020
Why?
Sensitivity and Specificity
1
2013
1979
0.020
Why?
Rats, Inbred Dahl
1
2008
8
0.020
Why?
Complement C1q
1
2008
10
0.020
Why?
Transforming Growth Factor beta3
1
2008
16
0.020
Why?
Thiosemicarbazones
1
2008
6
0.020
Why?
Methemoglobinemia
1
2008
10
0.020
Why?
Health Services Accessibility
1
2012
390
0.020
Why?
Recurrence
2
2008
1132
0.020
Why?
Bone Marrow Transplantation
1
1989
285
0.020
Why?
Hypertrophy, Right Ventricular
1
2008
33
0.020
Why?
Lymphoma, T-Cell, Cutaneous
2
1998
12
0.020
Why?
Incidence
1
2012
1561
0.020
Why?
Luciferases, Firefly
1
2007
12
0.020
Why?
Karyotyping
1
1987
250
0.020
Why?
Xenobiotics
1
2007
7
0.020
Why?
Informatics
1
2007
5
0.020
Why?
Gadolinium DTPA
1
2008
261
0.020
Why?
Herb-Drug Interactions
1
2007
4
0.020
Why?
Cytarabine
1
2008
218
0.020
Why?
Antigens, Surface
1
1987
101
0.020
Why?
Molecular Diagnostic Techniques
1
2007
69
0.020
Why?
Mycophenolic Acid
1
2007
85
0.020
Why?
Aerosols
1
2007
44
0.020
Why?
Bone Marrow Examination
1
1987
48
0.020
Why?
Hydroxytestosterones
1
2006
1
0.020
Why?
Plant Preparations
1
2007
19
0.020
Why?
Mitogen-Activated Protein Kinases
1
2008
222
0.020
Why?
Pharmacokinetics
1
2006
12
0.020
Why?
Genes, Reporter
1
2007
266
0.020
Why?
Menogaril
1
1986
3
0.020
Why?
Infusions, Parenteral
1
1986
50
0.020
Why?
Uterine Cervical Neoplasms
1
1989
273
0.020
Why?
Thymine
1
1986
17
0.020
Why?
Hyponatremia
1
1986
25
0.020
Why?
Digestive System
1
1986
42
0.020
Why?
Administration, Inhalation
1
2007
186
0.020
Why?
Thyroid Neoplasms
1
2011
405
0.020
Why?
Enzyme Activation
1
2008
692
0.020
Why?
Empirical Research
2
1997
19
0.020
Why?
Vitamins
1
2007
81
0.020
Why?
Dietary Supplements
1
2007
126
0.020
Why?
Cell Survival
1
2008
966
0.020
Why?
Platelet Aggregation Inhibitors
1
2007
131
0.020
Why?
Mephenytoin
1
2004
2
0.020
Why?
Cytochrome P-450 CYP2B6
1
2004
6
0.020
Why?
Fluvoxamine
1
2004
6
0.020
Why?
Lung Diseases
1
2007
261
0.020
Why?
Receptors, Endothelin
1
2004
13
0.020
Why?
Sequence Deletion
1
2005
203
0.020
Why?
Hemodynamics
1
2008
709
0.020
Why?
Statistics, Nonparametric
1
2004
307
0.020
Why?
Vincristine
2
1997
111
0.010
Why?
Analgesia, Patient-Controlled
1
2003
16
0.010
Why?
Indicators and Reagents
1
2003
72
0.010
Why?
Contrast Media
1
2008
1068
0.010
Why?
Carrier Proteins
1
2007
672
0.010
Why?
Substance-Related Disorders
1
2007
387
0.010
Why?
Heart Ventricles
1
2008
759
0.010
Why?
Risk
1
2004
672
0.010
Why?
Dexamethasone
1
2004
327
0.010
Why?
Propofol
1
2002
90
0.010
Why?
Global Health
1
2002
192
0.010
Why?
Catalysis
1
2001
203
0.010
Why?
Cyclin-Dependent Kinases
1
2000
43
0.010
Why?
Hot Temperature
1
2000
205
0.010
Why?
Rectum
1
2000
142
0.010
Why?
Spectrophotometry, Ultraviolet
1
1998
43
0.010
Why?
Shivering
1
1998
4
0.010
Why?
Dermatitis, Exfoliative
1
1998
3
0.010
Why?
Methotrexate
2
1989
249
0.010
Why?
Pentoxifylline
1
1998
9
0.010
Why?
Platelet Count
2
1989
92
0.010
Why?
Cell Count
1
1998
193
0.010
Why?
Persons
1
1997
6
0.010
Why?
Neoplasms, Experimental
1
1999
269
0.010
Why?
Control Groups
1
1997
15
0.010
Why?
Federal Government
1
1997
28
0.010
Why?
Paternalism
1
1997
24
0.010
Why?
Vasodilator Agents
1
1998
152
0.010
Why?
Chromatography, Ion Exchange
1
1997
34
0.010
Why?
Patient Advocacy
1
1997
49
0.010
Why?
Acquired Immunodeficiency Syndrome
1
1997
78
0.010
Why?
Radiography
1
1999
809
0.010
Why?
Vulnerable Populations
1
1997
76
0.010
Why?
Ligands
1
1998
432
0.010
Why?
Neoplasm Invasiveness
1
1998
540
0.010
Why?
Mass Spectrometry
1
1997
188
0.010
Why?
Brain
1
1986
2196
0.010
Why?
Enzyme Induction
1
1995
88
0.010
Why?
Karnofsky Performance Status
1
1995
40
0.010
Why?
Menopause
1
1995
71
0.010
Why?
Catheterization, Central Venous
1
1996
116
0.010
Why?
CD4-CD8 Ratio
1
1994
18
0.010
Why?
Cultural Diversity
1
1995
51
0.010
Why?
Truth Disclosure
1
1995
87
0.010
Why?
Educational Status
1
1995
185
0.010
Why?
Cyclohexenes
1
1994
5
0.010
Why?
Benzofurans
1
1994
8
0.010
Why?
Lymphocyte Subsets
1
1994
63
0.010
Why?
Trust
1
1995
92
0.010
Why?
Professional Staff Committees
1
1992
7
0.010
Why?
Cancer Care Facilities
1
1992
28
0.010
Why?
Hemoglobin A
1
1992
8
0.010
Why?
2-Chloroadenosine
1
1992
5
0.010
Why?
Deoxyadenosines
1
1992
23
0.010
Why?
Platinum
1
1992
62
0.010
Why?
Diabetes Complications
1
1993
208
0.010
Why?
Respiratory Insufficiency
1
1993
149
0.010
Why?
Electrocardiography
1
1993
475
0.010
Why?
Absorption
1
1989
25
0.010
Why?
Acid Phosphatase
1
1988
33
0.010
Why?
Chlorambucil
1
1988
23
0.010
Why?
Chromatography, Gas
1
1988
28
0.010
Why?
Costs and Cost Analysis
1
1987
152
0.000
Why?
Platelet Transfusion
1
1986
14
0.000
Why?
Erythrocyte Transfusion
1
1986
60
0.000
Why?